RT Journal Article
SR Electronic
T1 Fibromyalgia syndrome.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1415
OP 1425
VO 34
IS 6
A1 Philip Mease
A1 Lesley M Arnold
A1 Robert Bennett
A1 Annelies Boonen
A1 Dan Buskila
A1 Serena Carville
A1 Amy Chappell
A1 Ernest Choy
A1 Daniel Clauw
A1 Dina Dadabhoy
A1 Michael Gendreau
A1 Don Goldenberg
A1 Geoffrey Littlejohn
A1 Susan Martin
A1 Philip Perera
A1 I Jon Russell
A1 Lee Simon
A1 Michael Spaeth
A1 David Williams
A1 Leslie Crofford
YR 2007
UL http://www.jrheum.org/content/34/6/1415.abstract
AB The fibromyalgia syndrome (FM) workshop at OMERACT 8 continued the work initiated in the first FM workshop at OMERACT 7 in 2004. The principal objectives were to work toward consensus on core domains for assessment in FM studies, evaluate the performance quality of outcome measures used in a review of recent trials in FM, and discuss the research agenda of the FM working group. An initiative to include the patient perspective on identification and prioritization of domains, consisting of focus groups and a patient Delphi exercise, was completed prior to OMERACT 8. Patient-identified domains were, for the most part, similar to those identified by clinician-investigators in terms of symptoms and relative importance. However, patients identified certain domains, such as stiffness, that were not included by physicians, and emphasized the importance of domains such as dyscognition and impaired motivation. Many of the principal domains agreed upon by the clinician-investigators, patients, and OMERACT participants, including pain, fatigue, sleep, mood, and global measures, have been used in clinical trials and performed well when viewed through the OMERACT filter. The research agenda items reviewed and approved for continued study included development of objective "biomarkers" in FM, development of a responder index for FM, and coordination with the WHO's International Classification of Functioning Disability and Health (ICF) Research Branch and the US National Institutes of Health's Patient Reported Outcome Measures Information System network (PROMIS) to develop improved measures of function, quality of life, and participation. The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM.